AbbVie Inc. (ABBV)
NYSE · Healthcare · analysed October 12, 2026
AbbVie Inc. is a global research-based biopharmaceutical company that was established in 2013 following its spin-off from Abbott Laboratories. The company focuses on discovering, developing, and commercializing advanced therapies across core areas including immunology, oncology, neuroscience, eye care, and medical aesthetics. Currently, AbbVie is focused on driving growth through its next-generation immunology drugs, Skyrizi and Rinvoq, to offset biosimilar competition for its legacy blockbuster Humira, while expanding its oncology and neuroscience pipelines through strategic acquisitions and late-stage clinical initiatives.
Executive summary
AbbVie has executed a successful commercial transition past Humira biosimilar erosion, returning to top-line growth driven by rapid expansion in its core immunology assets Skyrizi and Rinvoq alongside resilient aesthetics and neuroscience franchises1. While the company generates strong free cash flow and maintains healthy pipeline momentum, financial leverage remains elevated from major acquisitions, and domestic concentration exposes long-term earnings to U.S. statutory drug price negotiations1,24. At current valuation levels following a strong multi-month share advance, the risk-reward profile is balanced4.
Sources cited here, 3 of 32
- 1investors.abbvie.com
- 4financecharts.com
- 24trefis.com
Key figures
- Market cap
- $488.6B
- P/E, trailing
- 78.1
- P/E, next 12 months
- 18.4
- Revenue growth, last fiscal year
- 8.6%
- Net margin, last fiscal year
- 6.8%
The full analysis adds sections on competition, financials and valuation, recent news, upcoming catalysts, institutional investors and fund letters. See the plans or join the waitlist.